<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.910174</article-id><article-id pub-id-type="publisher-id">ACM-32454</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20191000000_62490479.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胃蛋白酶原、胃泌素17与胃癌前病变进展风险的纵向研究
  Longitudinal Study on the Relationship between Pepsinogen, Gastrin-17 and the Risk of Gastric Precancerous Lesions
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>方</surname><given-names>年富</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>庆霞</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>卫生</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>克红</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>光勇</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>余</surname><given-names>恕玉</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>江西省景德镇市第二人民医院消化内科，江西 景德镇</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>27</day><month>09</month><year>2019</year></pub-date><volume>09</volume><issue>10</issue><fpage>1133</fpage><lpage>1137</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨血清胃蛋白酶原I、II (pepsinogen, PGI、II)与胃泌素-17 (gatrin-17, G-17)在胃癌前病变中的诊断价值。方法：选择2018年1月~10月有消化道症状患者98例，根据胃镜检查及病理结果分为胃溃疡组(32例)、萎缩性胃炎组(21例)、肠上皮化生组(25例)、低级别上皮内瘤变组(20例)，选取同期30例非萎缩性胃炎者作为对照组。应用ELISA法检测比较五组血清PGI、PGII、胃蛋白酶原比值(PGR即PGI/PGII比值)、G-17水平。结果：胃溃疡组PGI、PGII水平明显高于萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组及对照组，差异有统计学意义(P &lt; 0.05)；PGR值变化不明显，差异无统计学意义(P &gt; 0.05)。萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组中PGI、PGR值低于对照组，差异有统计学意义(P &lt; 0.05)；萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组间PGI、PGR水平值比较无明显差异(P &gt; 0.05)。萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组与对照组PGII比较无统计学意义(P &gt; 0.05)。萎缩性胃炎组血清G-17水平与对照组比较，差异无统计学意义(P &gt; 0.05)；胃溃疡组、肠上皮化生组、低级别内瘤变组血清G-17均显著高于对照组与萎缩性胃炎组，差异有统计学意义(P &lt; 0.05)。胃溃疡组、肠上皮化生组、低级别内瘤变组间G-17比较，差异无统计学意义(P &gt; 0.05)。结论：血清PGI、PGII、PGR以及G-17的变化对胃癌前病变进展风险有一定的临床价值，值得我们深入研究。&lt;br/&gt;Objective: To explore the diagnostic value of serum pepsinogen and gastrin-17 in precancerous lesions of gastric cancer. Methods: From January to October 2018, 98 patients with digestive tract symptoms were divided into three groups according to gastroscopy and pathology: gastric ulcer group (n = 32), atrophic gastritis group (n = 21), intestinal metaplastic group (n = 25) and low grade intraepithelial neoplastic group (n = 20). In the same period, 30 healthy subjects were selected as the control group. ELISA method was used to detect and compare the levels of serum PGI, PGII and PGR, G-17 in the five groups. Results: The level of PGI, PGII in gastric ulcer group was significantly higher than that in atrophic gastritis group, intestinal metaplastic group, low grade intraepithelial neoplastic group and control group (P &lt; 0.05), but there was no significant difference in PGR value between the two groups (P &gt; 0.05). PGI and PGR values in atrophic gastritis group, intestinal epithelial metaplasia group and low-grade intraepithelial neoplasia group were lower than those in control group (P &lt; 0.05). There was no significant difference in PGI and PGR levels between atrophic gastritis group, intestinal metaplasia group and low-grade intraepithelial tumor group (P &gt; 0.05). There was no significant difference in PGII between atrophic gastritis group, intestinal metaplastic group and low grade intraepithelial neoplastic group compared with the control group (P &gt; 0.05). There was no significant difference in serum G-17 level between atrophic gastritis group and control group (P &gt; 0.05), but the serum G-17 level in gastric ulcer group, intestinal metaplastic group and low grade intratumor group was significantly higher than that in control group and atrophic gastritis group (P &lt; 0.05). There was no significant difference in G-17 between gastric ulcer group, intestinal metaplastic group and low grade intratumoral degeneration group (P &gt; 0.05). Conclusions: The changes of serum PGI, PGII, PGR and G-17 have certain clinical value in the diagnosis of precancerous lesions of gastric cancer, which is worthy of further study. 
  
 
</p></abstract><kwd-group><kwd>胃癌，胃蛋白酶原，胃泌素-17，癌前病变, Gastric Cancer</kwd><kwd> Pepsinogen</kwd><kwd> Gastrin-17</kwd><kwd> Precancerous Lesion</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胃蛋白酶原、胃泌素17与胃癌前病变进展风险的纵向研究<sup> </sup></title><p>方年富，何庆霞，杨卫生，贾克红，袁光勇，余恕玉</p><p>江西省景德镇市第二人民医院消化内科，江西 景德镇</p><p><img src="//html.hanspub.org/file/3-1571043x1_hanspub.png" /></p><p>收稿日期：2019年9月12日；录用日期：2019年10月3日；发布日期：2019年10月10日</p><disp-formula id="hanspub.32454-formula14"><graphic xlink:href="//html.hanspub.org/file/3-1571043x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨血清胃蛋白酶原I、II (pepsinogen, PGI、II)与胃泌素-17 (gatrin-17, G-17)在胃癌前病变中的诊断价值。方法：选择2018年1月~10月有消化道症状患者98例，根据胃镜检查及病理结果分为胃溃疡组(32例)、萎缩性胃炎组(21例)、肠上皮化生组(25例)、低级别上皮内瘤变组(20例)，选取同期30例非萎缩性胃炎者作为对照组。应用ELISA法检测比较五组血清PGI、PGII、胃蛋白酶原比值(PGR即PGI/PGII比值)、G-17水平。结果：胃溃疡组PGI、PGII水平明显高于萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组及对照组，差异有统计学意义(P &lt; 0.05)；PGR值变化不明显，差异无统计学意义(P &gt; 0.05)。萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组中PGI、PGR值低于对照组，差异有统计学意义(P &lt; 0.05)；萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组间PGI、PGR水平值比较无明显差异(P &gt; 0.05)。萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组与对照组PGII比较无统计学意义(P &gt; 0.05)。萎缩性胃炎组血清G-17水平与对照组比较，差异无统计学意义(P &gt; 0.05)；胃溃疡组、肠上皮化生组、低级别内瘤变组血清G-17均显著高于对照组与萎缩性胃炎组，差异有统计学意义(P &lt; 0.05)。胃溃疡组、肠上皮化生组、低级别内瘤变组间G-17比较，差异无统计学意义(P &gt; 0.05)。结论：血清PGI、PGII、PGR以及G-17的变化对胃癌前病变进展风险有一定的临床价值，值得我们深入研究。</p><p>关键词 :胃癌，胃蛋白酶原，胃泌素-17，癌前病变</p><disp-formula id="hanspub.32454-formula15"><graphic xlink:href="//html.hanspub.org/file/3-1571043x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1571043x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-1571043x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>胃癌(gastric cancer)是起源于胃黏膜上皮的恶性肿瘤，在我国各种恶性肿瘤中发病率居首位。有研究指出 [<xref ref-type="bibr" rid="hanspub.32454-ref1">1</xref>] ，胃癌是从浅表性胃炎起，经胃息肉或萎缩性胃炎、肠上皮化生、上皮内瘤变等癌前病变，最后发展成为胃癌，其发生是由多种致病因素、多步骤进行性发展的慢性过程。因此，监测癌前疾病对胃癌的早期筛查具有重要意义。胃镜是胃癌早期筛查最重要的检查方式，但由于我国人口基数大、内镜医师数量少的客观原因，限制了胃镜在大规模胃癌筛查中的应用。近年来，血清中胃蛋白酶原I、II (pepsinogen, PGI、II)与胃泌素-17 (gatrin-17, G-17)在胃癌和萎缩性胃炎的筛选中的价值备受关注，应用血清学检测进行胃癌前病变的筛查具有重要意义。本文就PGI、II与G-17在胃癌前病变中的临床价值进行探讨。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选择2018年1月~10月我院收治的消化道患者98例作为研究对象。本研究经医院伦理委员会审批通过，患者知情同意并签署知情同意书。根据胃镜检查及病理结果分为胃溃疡组32例、萎缩性胃炎组21例、上皮化生组25例、低级别上皮内瘤变组20例，选取同期30例非萎缩性胃炎者作为对照组。胃溃疡组男18例，女14例，年龄25岁至78岁，平均年龄(51.31 &#177; 11.21)；萎缩性胃炎组男10例，女11例，年龄31岁至76岁，平均年龄(54.34 &#177; 10.80)；肠上皮化生组男14例，女11例，年龄33岁至774岁，平均年龄(53.93 &#177; 10.80)；低级别上皮内瘤变组男9例，女11例，年32岁至77岁，平均年龄(53.23 &#177; 10.96)；对照组男16例，女14例，年龄27岁至84岁，平均年龄(50.02 &#177; 12.04)。五组在性别、年龄等资料比较，差异无统计学意义(P &gt; 0.05)，具有可比性。</p></sec><sec id="s4_2"><title>2.2. 纳入及排除标准</title><p>纳入标准：① 符合《消化性溃疡诊断与治疗规范(2016，西安)》 [<xref ref-type="bibr" rid="hanspub.32454-ref2">2</xref>] 对胃溃疡诊断标准、符合《慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识》 [<xref ref-type="bibr" rid="hanspub.32454-ref3">3</xref>] 对萎缩性胃炎、肠上皮化生、低级别上皮内瘤变的诊断标准；② 年龄18~85岁。排除标准：① 正服用抗凝药；② 两周内使用PPI、制酸剂、护胃剂等；③ 有胃部手术史(包括外科手术、微创EMR、ESD)；④ 有严重的心、肝、肾功能不全或严重精神疾病。</p></sec><sec id="s4_3"><title>2.3. 方法</title><p>所有研究对象均进行胃镜检查，电子染色进行精查，分别于胃窦和胃体病变明显部位取2块胃黏膜组织，进行活检病理检查。所有受检者均于清晨抽取5 ml空腹外周静脉血，离心后取上层血清，以酶联免疫吸附测定法(ELISA)检测血清PGI、PGII、G-17水平，并计算胃蛋白酶原比值(PGR即PGI/PGII比值)。试剂盒均由芬兰Biohit HealthCare提供，具体步骤严格按说明书进行操作。</p></sec><sec id="s4_4"><title>2.4. 观察指标</title><p>比较五组PGI、PGII、G-17，并计算PGR。PGI参考值：70.0~165.0 ug/L；PGII参考值：3.0~15.0 ug/L；G-17参考值：1.0~15.0 pmol/L。PGR参考值 &gt; 7。</p></sec><sec id="s4_5"><title>2.5. 统计学方法</title><p>采用SPSS 21.0统计学软件进行数据分析。计量资料以(x &#177; s)表示，采用t检验。以P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>胃溃疡组PGI、PGII水平明显高于萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组及对照组，差异有统计学意义(P &lt; 0.05)；PGR值变化不明显，差异无统计学意义(P &gt; 0.05)。萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组中PGI、PGR值低于对照组，差异有统计学意义(P &lt; 0.05)；萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组间PGI、PGR水平值比较无明显差异(P &gt; 0.05)；萎缩性胃炎组、肠上皮化生组、低级别上皮内瘤变组与对照组PGII比较无统计学意义(P &gt; 0.05)。萎缩性胃炎组血清G-17水平与对照组比较，差异无统计学意义(P &gt; 0.05)；胃溃疡组、肠上皮化生组、低级别内瘤变组血清G-17均显著高于对照组与萎缩性胃炎组，差异有统计学意义(P &lt; 0.05)。胃溃疡组、肠上皮化生组、低级别内瘤变组间G-17比较，差异无统计学意义(P &gt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of serum PGI, PGII, PGR and G-17 in each group (x &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >PGI (ug/L)</th><th align="center" valign="middle" >PGII (ug/L)</th><th align="center" valign="middle" >PGR</th><th align="center" valign="middle" >G-17 (pmol/L)</th></tr></thead><tr><td align="center" valign="middle" >胃溃疡组</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >131.83 &#177; 24.62<sup>*</sup></td><td align="center" valign="middle" >15.31 &#177; 6.65<sup>*</sup></td><td align="center" valign="middle" >9.13 &#177; 1.33</td><td align="center" valign="middle" >15.34 &#177; 4.22<sup>*</sup></td></tr><tr><td align="center" valign="middle" >萎缩性胃炎</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >46.44 &#177; 18.92<sup>*</sup></td><td align="center" valign="middle" >9.40 &#177; 1.36</td><td align="center" valign="middle" >4.46 &#177; 2.01<sup>*</sup></td><td align="center" valign="middle" >8.69 &#177; 3.81</td></tr><tr><td align="center" valign="middle" >肠上皮化生组</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >50.41 &#177; 11.09<sup>*</sup></td><td align="center" valign="middle" >8.13 &#177; 2.21</td><td align="center" valign="middle" >5.82 &#177; 2.27<sup>*</sup></td><td align="center" valign="middle" >14.26 &#177; 1.06<sup>*</sup></td></tr><tr><td align="center" valign="middle" >低级别上皮内瘤变组</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >48.63 &#177; 12.35<sup>*</sup></td><td align="center" valign="middle" >9.37 &#177; 3.58</td><td align="center" valign="middle" >4.75 &#177; 1.50<sup>*</sup></td><td align="center" valign="middle" >16.62 &#177; 5.48<sup>*</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >95.29 &#177; 23.47</td><td align="center" valign="middle" >10.93 &#177; 2.35</td><td align="center" valign="middle" >9.38 &#177; 1.59</td><td align="center" valign="middle" >9.31 &#177; 2.48</td></tr></tbody></table></table-wrap><p>表1. 各组血清中PGI、PGII、PGR及G-17比较(x &#177; s)</p><p>注：与对照组比较，<sup>*</sup>P &lt; 0.05。</p></sec><sec id="s6"><title>4. 讨论</title><p>胃的癌前病变包括胃溃疡、胃息肉、萎缩性胃炎、肠上皮化生、上皮内瘤变等等，这些癌前疾病在不良条件的促进下极易发展为胃癌，由健康胃黏膜–浅表性胃炎–萎缩性胃炎–肠上皮化生–上皮内瘤变–胃癌的进展模式逐渐被大家认同 [<xref ref-type="bibr" rid="hanspub.32454-ref1">1</xref>] 。如何提高早期胃癌检出率，尤其是胃癌前病变的检出率将是降低胃癌病死率关键。目前，我国根据国情已逐步开展针对胃癌高危人群首先检测血清PG和G-17水平，再根据检测结果选择性胃镜精查的两轮筛查方案，并取得了一定的成效 [<xref ref-type="bibr" rid="hanspub.32454-ref4">4</xref>] 。</p><p>血清PG主要是由胃黏膜分泌，主要包括PGI与PGII，可以间接地反映人体不同部位胃黏膜的功能和形态，从而反映胃黏膜的萎缩程度 [<xref ref-type="bibr" rid="hanspub.32454-ref5">5</xref>] 。当胃体黏膜出现病变时，PGI随胃酸分泌增加或减少而升高或降低；当胃底黏膜发生病变时，则PGII含量发生改变；当胃黏膜萎缩时，PGR随病情的进展呈进行性降低 [<xref ref-type="bibr" rid="hanspub.32454-ref6">6</xref>] 。大多数的研究表明 [<xref ref-type="bibr" rid="hanspub.32454-ref7">7</xref>] ，低水平的血清PGI和PGR是萎缩性胃炎的指标。通常将血清PGR &lt; 3，PGI &lt; 70 ug/l作为诊断萎缩性胃炎的临界值。胃溃疡患者中血清PG水平在诸多研究结果中有所差别。陈春春等 [<xref ref-type="bibr" rid="hanspub.32454-ref8">8</xref>] 研究结果显示，胃溃疡及十二指肠溃疡血清PGI、PGII水平较正常人群显著升高；但Manabe, S.等 [<xref ref-type="bibr" rid="hanspub.32454-ref9">9</xref>] 、Cho, J.H.等 [<xref ref-type="bibr" rid="hanspub.32454-ref10">10</xref>] 的研究报道，胃溃疡组患者血清PGI、PGR水平均低于正常人群。本研究结果发现，胃溃疡组PGI、PGII水平较对照组显著升高，差异有统计学意义(P &lt; 0.05)，可能与胃溃疡患者胃酸分泌增多，导致血清PG分泌增加以及胃黏膜通透性增加有关。目前对肠上皮化生及上皮内瘤变患者PG水平的研究较少。李梦颖等 [<xref ref-type="bibr" rid="hanspub.32454-ref11">11</xref>] 报道31例低级别上皮内瘤变组及20例高级别上皮内瘤变组较67例对照组血清PGI水平、PGR均显著降低(P &lt; 0.01)，同时高于54例胃癌患者(P &lt; 0.05)。本研究发现肠上皮化生组及低级别上皮内瘤变组PGI、PGR水平较对照组均显著降低，有统计学意义，但与萎缩性胃炎组无明显差异。</p><p>血清G-17由胃窦G细胞合成和分泌，对胃黏膜具有营养作用，其可有效激活诸多信号通路，发挥抗侵袭、抗凋亡、抗炎性反应等作用 [<xref ref-type="bibr" rid="hanspub.32454-ref12">12</xref>] 。随着研究的深入，血清G-17随癌前病变的进展可能呈现出不同变化。当黏膜萎缩发生在胃体时，低胃酸水平会负反馈引起血清G-17水平升高；但当黏膜萎缩发生在胃窦时，胃窦G细胞数量减少必然引起血清G-17水平降低；当黏膜萎缩累及全胃时，其血清G-17水平略高于胃窦黏膜萎缩，但低于胃体黏膜萎缩。本研究显示萎缩性胃炎患者血清G-17水平与对照组无明显差异(P &gt; 0.05)，可能与实验设计时未严格区分黏膜萎缩部位有关。现在研究认为 [<xref ref-type="bibr" rid="hanspub.32454-ref13">13</xref>] ，G-17参与胃溃疡的形成：胃黏膜发生炎症时，炎性因子释放可间接促进G-17分泌增加，引起胃酸分泌增多，高胃酸可加重对胃壁黏膜组织损伤，并促进胃溃疡形成。本研究同样显示胃溃疡组血清G-17水平较非萎缩性胃炎显著升高(P &lt; 0.05)。本研究显示肠上皮化生、上皮内瘤变患者血清G-17水平较对照组显著升高(P &lt; 0.05)，与李梦颖等 [<xref ref-type="bibr" rid="hanspub.32454-ref11">11</xref>] 的报道一致。尽管在本研究中萎缩性胃炎患者血清G-17水平无明显变化，但在胃溃疡、肠上皮化生、低级别上皮内瘤变患者中血清G-17呈升高的趋势，提示血清G-17是筛查胃癌的重要指标。</p></sec><sec id="s7"><title>5. 小结</title><p>综上所述，血清PGI、PGII、PGR以及G-17的变化在胃癌前病变进展风险中有一定的临床诊断价值，值得我们深入研究。由于本研究标本量不大，没有采用联合检测方式提高胃癌及癌前病检测的敏感性及特异性，因此，还有待进一步研究验证。</p></sec><sec id="s8"><title>基金项目</title><p>江西省卫生计生委科技计划(编号：20187180)。</p></sec><sec id="s9"><title>文章引用</title><p>方年富,何庆霞,杨卫生,贾克红,袁光勇,余恕玉. 胃蛋白酶原、胃泌素17与胃癌前病变进展风险的纵向研究Longitudinal Study on the Relationship between Pepsinogen, Gastrin-17 and the Risk of Gastric Precancerous Lesions[J]. 临床医学进展, 2019, 09(10): 1133-1137. https://doi.org/10.12677/ACM.2019.910174</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.32454-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">马英睿, 左赞, 郭强. 血清胃功能检测对萎缩性胃炎诊断及胃癌风险评估的研究进展[J]. 昆明医科大学学报, 2018, 39(8): 124-128.</mixed-citation></ref><ref id="hanspub.32454-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华消化杂志编委会. 消化性溃疡诊断与治疗规范(2016年, 西安)[J]. 中华消化杂志, 2016, 36(8): 508-513.</mixed-citation></ref><ref id="hanspub.32454-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会病理分会消化病理学组筹备组. 慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识[J]. 中华病理学杂志, 2017, 46(5): 289-293.</mixed-citation></ref><ref id="hanspub.32454-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">陈蕾, 顾云峰, 詹爱霞, 等. 改良ABCD法在胃癌高危人群中的筛查价值[J]. 肿瘤, 2017, 37(11): 1209-1217.</mixed-citation></ref><ref id="hanspub.32454-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yoshida, T., Kato, J., Inoue, I., et al. (2014) Cancer Development Based on Chronic Active Gastritis and Resulting Gastric Atrophy as Assessed by Serum Levels of Pepsinogen and Helicobacter pylori Antibody Titer. International Journal of Cancer, 134, 1445-1457. &lt;br&gt;https://doi.org/10.1002/ijc.28470</mixed-citation></ref><ref id="hanspub.32454-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Al-Rawashdeh, O., Ismail, Z.B., Talafha, A. and Al-Momani, A. (2017) Changes of Hematological and Biochemical Parameters and Levels of Pepsinogen, Histamine and Prostaglandins in Dairy Cows Affected with Left Displacement of the Abomasum. Polish Journal of Veterinary Sciences, 20, 13-18. &lt;br&gt;https://doi.org/10.1515/pjvs-2017-0002</mixed-citation></ref><ref id="hanspub.32454-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">张玲霞, 庄坤, 张沥, 等. 血清胃蛋白酶原和胃泌素-17与萎缩性胃炎关系的研究[J]. 陕西医学杂志, 2014, 43(3): 279-282.</mixed-citation></ref><ref id="hanspub.32454-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">陈春春, 罗和生, 成镀, 等. 血清胃蛋白酶原在慢性胃部病变中变化的临床研究[J]. 胃肠病学和肝病学杂志, 2018, 27(11): 1265-1269.</mixed-citation></ref><ref id="hanspub.32454-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Manabe, S., Mukaisho, K.I., Yasuoka, T., et al. (2017) Gastric Adenocarcinoma of Fundic Gland Type Spreading to Heterotopic Gastric Glands. World Journal of Gastroenterology, 23, 7047-7053.  
&lt;br&gt;https://doi.org/10.3748/wjg.v23.i38.7047</mixed-citation></ref><ref id="hanspub.32454-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cho, J.H., Jeon, S.R., Kim, H.G., Jin, S.-Y. and Park, S. (2017) The Serum Pepsinogen Levels for Risk Assessment of Gastric Neoplasms: New Proposal from a Case-Control Study in Korea. Medicine, 96, e7603.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000007603</mixed-citation></ref><ref id="hanspub.32454-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李梦颖, 马晨, 焦晨阳, 等. 血清胃蛋白酶原和胃泌素-17在胃癌和癌前病变筛查中的价值[J]. 胃肠病学, 2017, 22(9): 539-543.</mixed-citation></ref><ref id="hanspub.32454-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yang, H.J., Xu, W.J., Guan, Y.H., et al. (2016) Expression of Glut-1 and HK-II in Pancreatic Cancer and Their Impact on Prognosis and FDG Accumulation. Translational Oncology, 9, 583-591.  
&lt;br&gt;https://doi.org/10.1016/j.tranon.2016.08.004</mixed-citation></ref><ref id="hanspub.32454-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">陈莫耶, 徐倩, 孙丽萍, 等. 血清胃泌素17水平与胃癌及癌前疾病的相关性研究[J]. 胃肠病学和肝病学杂志, 2015, 24(2): 161-165.</mixed-citation></ref></ref-list></back></article>